hackint0sh/New-Dataset huggingface dataset:
The methods of access for epidural injections are characterized as transforaminal, interlaminar, or caudal. Caudal epidural injections (CEI) are often utilized as a diagnostic or therapeutic tool in a range of lumbosacral-originating spinal pain problems, and they are especially useful in patients with complicated lumbar epidural access diseases, such as post laminectomy syndrome. It is regarded as a very simple treatment in the realm of interventional pain management, and it is also recognized to have a reduced risk of inadvertent Dural puncture than other epidural techniques conditions: Postoperative Pain studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 80 type: ESTIMATED name: Fentanyl measure: Measurement of Post-operative Pain sex: ALL minimumAge: 21 Years maximumAge: 60 Years stdAges: ADULT facility: Al-Azhar University hospitals city: Cairo country: Egypt name: Mohamed Khalil, Resident role: CONTACT phone: +201001297071 email: khalil.mohamed24mkh@gmail.com lat: 30.06263 lon: 31.24967 hasResults: False
nctId: NCT06336135 id: 23-001 briefTitle: Reduction in Symptoms After Laser Therapy With Acorn aHFS overallStatus: ENROLLING_BY_INVITATION date: 2024-03-25 date: 2025-03 date: 2025-12 date: 2024-03-28 date: 2024-03-28 name: Acorn Biolabs Inc. class: INDUSTRY briefSummary: This study evaluates the severity and duration of symptoms experienced after laser therapy comparing four post-procedure topical products. Each product is applied to an individual region of interest (5 cm diameter) on the back or décolleté according to randomization code after laser therapy. The subject, blind to the product applied to each of 4 regions of interest, assesses eight symptoms daily for 14 days. Photography is performed daily. conditions: Skin Aging studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 50 type: ESTIMATED name: autologous hair follicle derived secretome measure: Reduction in severity and duration of symptoms sex: ALL minimumAge: 18 Years maximumAge: 60 Years stdAges: ADULT facility: Rejuuv Medi Spa city: Markham state: Ontario zip: L3R0M3 country: Canada lat: 43.86682 lon: -79.2663 hasResults: False
nctId: NCT06336122 id: 83904_1 id: R01DK135885-01 type: NIH link: https://reporter.nih.gov/quickSearch/R01DK135885-01 briefTitle: OASIS: Peer Support for T2DM in Appalachia (Peer Participant) acronym: OASIS overallStatus: RECRUITING date: 2024-02-21 date: 2025-12-31 date: 2026-03-31 date: 2024-03-28 date: 2024-04-08 name: University of Kentucky class: OTHER name: Department of Health and Human Services name: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) briefSummary: The goal of this clinical trial is to compare the effects of peer coaching models in older adults with unmanaged type two diabetes. The main questions it aims to answer are:
Retain records of contact, topics discussed, and general notes on interactions. Researchers will compare differences in the frequency of contact, as well as how peer coaches were matched to peer participants to see if efficacy of the intervention is altered between groups. conditions: Diabetes Mellitus, Type 2 studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: FACTORIAL primaryPurpose: HEALTH_SERVICES_RESEARCH masking: NONE count: 76 type: ESTIMATED name: Peer Coach Training - Weekly name: Peer Coach Training - Biweekly measure: Number of participants with change in A1c measure: Diabetes Empowerment measure: Quality of Life Index measure: Social Support measure: Depression Scale measure: Problem Areas in Diabetes measure: Diabetes Self-Management measure: Acts of Daily Living measure: Social Network Scale sex: ALL minimumAge: 55 Years maximumAge: 99 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Barren River Area Development District status: RECRUITING city: Bowling Green state: Kentucky zip: 42101 country: United States name: Michelle Hines role: CONTACT phone: 270-306-4036 email: michelle@bradd.org lat: 36.99032 lon: -86.4436 facility: UK HealthCare status: RECRUITING city: Hazard state: Kentucky zip: 41701 country: United States name: Kay Douthitt, MD role: CONTACT email: key.douthitt@uky.edu lat: 37.24954 lon: -83.19323 hasResults: False
nctId: NCT06336109 id: N-20220063-3 briefTitle: Fragmented Sleep, Pain, and Biomechanics overallStatus: RECRUITING date: 2024-01-26 date: 2024-12-31 date: 2024-12-31 date: 2024-03-28 date: 2024-04-03 name: Aalborg University class: OTHER briefSummary: This interventional study aims to test the effects of sleep disruption on pain sensitivity and biomechanics in healthy individuals during experimental knee and shoulder pain. The main question the study aims to answer is:
Participants will receive two injections a) Hypertonic saline (painful) in the knee and b) hypertonic saline (painful) in the upper arm. conditions: Pain conditions: Healthy conditions: Sleep Disturbance studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: BASIC_SCIENCE masking: NONE count: 30 type: ESTIMATED name: Hypertonic saline knee and shoulder injection measure: Knee Pain intensity (NRS 0-10) measure: Shoulder Pain intensity (NRS 0-10) measure: Pain sensitivity measure: The Pittsburgh Sleep Quality Index score measure: The Pain catastrophizing Scale score measure: The Hospital Anxiety and Depression Scale score measure: The Knee injury and Osteoarthritis Outcome Score measure: Rapid Assessment of Physical Activity score measure: Pain distribution by number of pixels marked on a body chart measure: Video-based motion capture measure: Quality of sleep (NRS 0-100) measure: Level of rest (NRS 0-100) sex: ALL minimumAge: 18 Years maximumAge: 45 Years stdAges: ADULT facility: Aalborg University status: RECRUITING city: Aalborg state: Nordjylland zip: 9000 country: Denmark name: Kristian K Petersen, Dr. Med role: CONTACT phone: (+45) 31697510 email: kkp@hst.aau.dk name: Emma Hertel, M. Sc. role: CONTACT phone: (+45) 60887473 email: eh@hst.aau.dk lat: 57.048 lon: 9.9187 hasResults: False
nctId: NCT06336096 id: VX23-548-017 briefTitle: A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation and Strength of Suzetrigine overallStatus: RECRUITING date: 2024-03-28 date: 2024-10 date: 2024-10 date: 2024-03-28 date: 2024-04-26 name: Vertex Pharmaceuticals Incorporated class: INDUSTRY briefSummary: The purpose of this study is to evaluate the pharmacokinetics (PK) of suzetrigine (SUZ; VX-548) and its metabolite along with its safety and tolerability, in healthy participants. conditions: Pain studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: CROSSOVER primaryPurpose: TREATMENT masking: NONE count: 72 type: ESTIMATED name: Suzetrigine name: Suzetrigine measure: Part A: Maximum Observed Plasma Concentration (Cmax) of SUZ measure: Part A: Area Under the Concentration Versus Time Curve From the Time of Dosing to the Last Measurable Concentration (AUC0-tlast) of SUZ measure: Part A: Area Under the Concentration Versus Time Curve From the Time of Dosing Extrapolated to Infinity (AUC0-inf) of SUZ measure: Part B: Cmax of SUZ measure: Part B: AUC0-tlast of SUZ measure: Part B: AUC0-inf of SUZ measure: Part A: Cmax of SUZ Metabolite measure: Part A: AUC0-tlast of SUZ Metabolite measure: Part A: AUC0-inf of SUZ Metabolite measure: Part A: Safety and Tolerability as Assessed by Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) measure: Part B: Cmax of SUZ Metabolite measure: Part B: AUC0-tlast of SUZ Metabolite measure: Part B: AUC0-inf of SUZ Metabolite measure: Part B: Safety and Tolerability as Assessed by Number of Participants with AEs and SAEs measure: Part C: Cmax of SUZ and its Metabolite measure: Part C: AUC0-tlast of SUZ and its Metabolite measure: Part C: AUC0-inf of SUZ and its Metabolite measure: Part C: Safety and Tolerability as Assessed by Number of Participants with AEs and SAEs sex: ALL minimumAge: 18 Years maximumAge: 55 Years stdAges: ADULT facility: Celerion - Tempe status: RECRUITING city: Tempe state: Arizona zip: 85283 country: United States lat: 33.41477 lon: -111.90931 hasResults: False
nctId: NCT06336083 id: RC31/23/0618 briefTitle: Familial Form of Carotid Web: a Doppler Ultrasound Study acronym: Family-WEB overallStatus: NOT_YET_RECRUITING date: 2024-06 date: 2026-06 date: 2026-06 date: 2024-03-28 date: 2024-04-11 name: University Hospital, Toulouse class: OTHER briefSummary: There is no evidence of familial forms of carotid web. The aim of this study is to determine the prevalence of carotid web among relatives of patient with carotid web using carotid doppler ultrasound. conditions: Carotid Web studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: SCREENING masking: NONE count: 90 type: ESTIMATED name: Doppler ultrasound measure: Evaluation of the prevalence of carotid web by doppler ultrasound in first-degree relatives of patients with carotid web. measure: Description of the clinical characteristics of relatives with carotid web and their index case. measure: Description of the morphological characteristics of relatives with carotid web and their index case. sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: CHU de Toulouse, Purpan city: Toulouse zip: 31059 country: France name: Louis FONTAINE, MD role: CONTACT phone: 05 61 77 93 67 phoneExt: +33 email: fontaine.l@chu-toulouse.fr lat: 43.60426 lon: 1.44367 hasResults: False
nctId: NCT06336070 id: 2024-FIS-3251696 id: CIACIF/2022/368 type: OTHER_GRANT domain: Regional Ministry of Education, Universities and Employment - Generalitat Valenciana briefTitle: Metabolic Flexibility and Autonomic Control After Muscle Power vs Metabolic Power Training in Postmenopausal Oncological Women: the POWER Health Study acronym: POWER Health overallStatus: RECRUITING date: 2024-01-01 date: 2027-12-31 date: 2028-12-31 date: 2024-03-28 date: 2024-04-04 name: University of Valencia class: OTHER name: Generalitat Valenciana briefSummary: POWER Health is a randomized clinical trial with a two-arm parallel design whose objectives are 1) to study metabolic flexibility and autonomic function (both capacities that describe cardiovascular health) in a sample of postmenopausal oncological women vs postmenopausal untreated controls (CT); and 2) to analyze the impact of two different 8-week physical exercise supervised interventions: HIIT training vs strength training focused on muscle power, on both cardiovascular capacities in these populations. conditions: Breast Cancer Female conditions: Cardiometabolic Syndrome conditions: Metabolism Disorder, Lipid conditions: Autonomic Dysfunction conditions: Cardiovascular Diseases in Old Age studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 56 type: ESTIMATED name: HIIT program (8 weeks) name: MPI program (8 weeks) measure: Fat oxidation during incremental test measure: Detrended Fluctuation Analysis measure: Weight measure: Height measure: Calf, waist and hip circumferences. measure: Lean mass measure: Fat-free mass measure: Visceral adipose tissue measure: Bone Mass measure: Fat mass measure: Blood Pressure measure: Oxygen Saturation measure: Sarcopenia measure: Physical activity and sedentariness measure: Lactate measure: Rating Perceived Exertion measure: Visual Analogue Scale of Pain measure: Cadence measure: Mechanical Power measure: Muscle Power 5STS measure: Basal metabolic rate measure: Respiratory exheange ratio at rest measure: Fat oxidation at rest measure: Carbohydrate oxidation at rest measure: Carbohydrate oxidation during incremental test measure: Energy expenditure during incremental test measure: FATmax intensity measure: VO2peak measure: Sample Entropy measure: SD1/SD2 ratio measure: The root mean square of successive differences between normal heartbeats (RMSSD) sex: FEMALE minimumAge: 35 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Faculty of Physical Activity and Sport Sciences status: RECRUITING city: Valencia state: Comunidad Valenciana zip: 46010 country: Spain name: Cristina Blasco Lafarga, PhD role: CONTACT phone: 64372 phoneExt: 9638 email: m.cristina.blasco@uv.es name: Jordi Monferrer-Marín, Predoctoral student role: SUB_INVESTIGATOR name: Ainoa Roldán, PhD role: SUB_INVESTIGATOR name: Jørn Wulff Helge, PhD role: SUB_INVESTIGATOR lat: 39.46975 lon: -0.37739 hasResults: False
nctId: NCT06336057 id: RC31/23/0408 briefTitle: Mentalizating in Adults Suffering From Narcolepsy Type 1. acronym: NARCOMENTAL overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2024-04 date: 2025-12 date: 2024-03-28 date: 2024-03-28 name: University Hospital, Toulouse class: OTHER briefSummary: The main objective is to examine the potential mentalization impairments affecting a population suffering from narcolepsy type 1. Indeed, the hypothesis of this research is that mentalization could be impaired in narcoleptic patients. conditions: Narcolepsy Type 1 studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: PROSPECTIVE count: 60 type: ESTIMATED name: Mentalization measure: Comparison of mentalization abilities, in a population of patients with NT1 versus a control group. measure: Comparison and description of mentalization abilities in a population of patients versus controls. measure: Better characterization of the clinical impression of an altered subjective experience of the difficulties the patients are going through. measure: Determination of the existence of a correlation between the time of appearance of the first symptoms and the initiation of treatment and the level of mentalization in NT1 patients, or not. measure: Determination of the existence of a correlation between the age at the first symptoms of NT1 patients and mentalization abilities, or not. sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Centre de compétence Narcolepsies et Hypersomnies rares, CHU de Toulouse, Hôpital Pierre-Paul Riquet city: Toulouse zip: 31059 country: France name: Rachel DEBS, Dr role: CONTACT phone: 05 61 77 94 88 email: debs.r@chu-toulouse.fr lat: 43.60426 lon: 1.44367 hasResults: False
nctId: NCT06336044 id: Taufiller/22 briefTitle: Pre-marketing Clinical Trial to Evaluate the Safety and Efficacy of the Filler of Hyaluronic Acid Recombinant Collagen overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2024-11 date: 2025-01 date: 2024-03-28 date: 2024-03-28 name: Taumedika s.r.l. class: INDUSTRY name: Nextrasearch S.r.l.s. briefSummary: Study to validate the safety and efficacy of the Hyaluronic Acid +Collagen filler 20 patients will undergo through 3 visits one to asses the health and apply the filler one after 4 weeks to check the results one after 16 weeks for the final check and results validation Safety assessed with analysis of the Adverse Events conditions: Wrinkle conditions: Scar conditions: Laxity; Skin studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: 20 patients will undergo skin characterists measurments at time 0 at +4weeks and at +16 weeks primaryPurpose: TREATMENT masking: NONE count: 20 type: ESTIMATED name: Karisma measure: Safety: no adverse events measure: Efficacy: change of wrinkles and scars measure: Efficacy: change of wrinkles and scars measure: Efficacy: change of wrinkles and scars measure: Efficacy: change of wrinkles and scars measure: Duration of the efficacy sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06336031 id: 30002163 briefTitle: Impact of Blood Phobia on Fainting Susceptibility overallStatus: RECRUITING date: 2024-03-30 date: 2024-12 date: 2025-02 date: 2024-03-28 date: 2024-04-17 name: Simon Fraser University class: OTHER briefSummary: The primary purpose of this study is to characterize cardiovascular autonomic function to emotional stimuli (blood-injection-injury phobia \[needle phobia\]) during an orthostatic (upright) challenge in individuals with and without known needle phobia. It is well established that emotional stress can produce hypotensive (low blood pressure) reactions. Interestingly, these hypotensive reactions to venipuncture (even with minimal blood drawn), insulin injections, finger sticks for blood sugar monitoring, dental care, and vaccinations can affect up to a quarter of adults and appear to be uniquely associated with blood-injection-injury phobia rather than other phobias. These hypotensive reactions can ultimately lead to a vasovagal syncope (fainting) response, and lead to increased avoidance of medical and dental procedures as a result of this phobia. Ultimately, this has severe implications on public health and places additional strain on the Canadian healthcare system. Currently, there is limited understanding surrounding the initiation of this response. Additionally, a comprehensive profile of cardiovascular autonomic function during exposure to provoking stimuli during orthostatic stress has not been captured in the literature. We will test individuals with and without blood-injection-injury phobia using our standard approach while exposing them to emotional stimuli. conditions: Syncope, Vasovagal conditions: Blood, Injection, Injury Type Phobia studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER primaryPurpose: OTHER masking: NONE count: 20 type: ESTIMATED name: blood-injection-injury (BII) phobia stimuli name: neutral stimuli measure: Orthostatic Tolerance sex: ALL minimumAge: 18 Years maximumAge: 50 Years stdAges: ADULT facility: Simon Fraser University status: RECRUITING city: Burnaby state: British Columbia zip: V5A 1S6 country: Canada name: Vera E Lucci, PhD role: CONTACT phone: 7787828560 email: vlucci@sfu.ca name: Victoria E Claydon, PhD role: PRINCIPAL_INVESTIGATOR lat: 49.26636 lon: -122.95263 hasResults: False
nctId: NCT06336018 id: NN7535-7703 id: U1111-1289-2466 type: OTHER domain: World Health Organization (WHO) briefTitle: A Research Study on Etavopivat in Participants With and Without Liver Disease overallStatus: NOT_YET_RECRUITING date: 2024-03-29 date: 2025-07-04 date: 2025-07-04 date: 2024-03-28 date: 2024-03-28 name: Novo Nordisk A/S class: INDUSTRY briefSummary: The study investigates an investigational drug called etavopivat in participants with hepatic impairments and participants with normal hepatic function (matched controls). During the study, all participants will be given a single oral dose of etavopivat. All participants will take the etavopivat orally together with water. After dosing, the study will last for 7 to 9 days. conditions: Liver Diseases studyType: INTERVENTIONAL phases: PHASE1 allocation: NON_RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 48 type: ESTIMATED name: Etavopivat measure: Area under the etavopivat plasma concentration-time curve from 0 hours and extrapolated to infinity after a single dose (AUC0-inf, etavopivat) measure: Maximum observed etavopivat plasma concentration after a single dose (Cmax, etavopivat) measure: Area under the etavopivat plasma concentration-time curve from 0 hours to the last quantifiable concentration after a single dose (AUC0-last, etavopivat) measure: Time to maximum observed etavopivat plasma concentration after a single dose (tmax, etavopivat) measure: Terminal half-life for etavopivat after a single dose (t1/2, etavopivat) measure: Apparent plasma clearance of etavopivat after a single dose (CL/Fetavopivat) measure: Apparent volume of distribution of etavopivat after a single dose based on plasma concentration values (Vz/Fetavopivat) measure: Number of adverse events (AEs) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Orlando Clinical Research Center city: Orlando state: Florida zip: 32806 country: United States lat: 28.53834 lon: -81.37924 facility: Amer. Rrsch Corp-TX Liver Inst city: San Antonio state: Texas zip: 78215 country: United States lat: 29.42412 lon: -98.49363 hasResults: False
nctId: NCT06336005 id: NN6022-7683 briefTitle: A Study to See How Safe a New Medicine (NNC6022-0001) is in Healthy People overallStatus: RECRUITING date: 2024-03-28 date: 2024-10-17 date: 2024-10-17 date: 2024-03-28 date: 2024-04-15 name: Novo Nordisk A/S class: INDUSTRY briefSummary: The study is testing a new study medicine, which is being tested as a potential medicine to treat cardiometabolic diseases.
The study will last for about 10 months in total. conditions: Healthy Volunteers conditions: Cardiometabolic Diseases studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE maskingDescription: Sponsor staff involved in the clinical trial is masked according to company standard procedures. whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 48 type: ESTIMATED name: NNC6022-0001 name: Placebo (NNC6022-0001) measure: Number of treatment emergent adverse events (TEAE) measure: AUC0-t, SD; the area under the NNC6022 0001 plasma concentration-time curve from time 0 to last measurable plasma concentration after a single dose measure: AUC0-∞, SD; the area under the NNC6022 0001 plasma concentration-time curve from time 0 to infinity after a single dose measure: Cmax, SD; the maximum plasma concentration of NNC6022 0001 after a single dose measure: IL-1β, SD; ratio of <Timepoint> (time of the maximal plasma concentration of NNC6022 0001) to baseline sex: ALL minimumAge: 18 Years maximumAge: 55 Years stdAges: ADULT facility: ICON - location Groningen status: RECRUITING city: Groningen zip: 9728 NZ country: Netherlands lat: 53.21917 lon: 6.56667 hasResults: False
nctId: NCT06335992 id: Dnr 2022-00831-01 briefTitle: Tissue Regeneration in Patients With Chronic Obstructive Pulmonary Disease After an Exercise Intervention. acronym: T-Rex overallStatus: RECRUITING date: 2022-09-01 date: 2025-02-28 date: 2025-04-30 date: 2024-03-28 date: 2024-03-28 name: Uppsala University class: OTHER name: Lund University briefSummary: The main objective of this project is to identify mechanisms for lung regeneration in patients with COPD induced by exercise training. The hypothesis is that adjusted exercise training improves disease outcome in these patients by decrease remodelling processes linked to oxidative stress, inflammatory and/or immunological pathways in the lung. Along the way, the investigator also expect to identify (or validate) biomarkers mirroring systemic processes such as reduced inflammation and ameliorating the epithelial barrier in these patients. These events may additionally act as potential targets for interventions.
(iv) Investigate in vitro cell behaviour and remodelling/regenerative processes altered in COPD patients upon exercise training (aim 1). conditions: Chronic Obstructive Pulmonary Disease studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 80 type: ESTIMATED name: Exercise regime measure: Pulmonary Function measure: Physical capacity measure: Inflammation markers measure: Level of emphysema measure: Maximal physical capacity ( Wmax) measure: COPD Assessment Test (CAT) sex: ALL minimumAge: 50 Years maximumAge: 85 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Lund University status: RECRUITING city: Lund country: Sweden name: Gunilla Westergren Thorsson, Phd role: CONTACT phone: +4646222 00 00 email: gunilla.westergren-thorsson@med.lu.se name: Caroline Ms Larsson, Phd role: CONTACT phone: +46736673026 email: caroline.larsson@med.lu.se lat: 55.70584 lon: 13.19321 facility: Uppsala University status: RECRUITING city: Uppsala country: Sweden name: Margareta Mrs Emtner, Phd role: CONTACT phone: +46737594481 email: margareta.emtner@medsci.uu.se name: Christer Mr Janson, Phd role: CONTACT phone: +46186114115 email: christer.janson@medsci.uu.se lat: 59.85882 lon: 17.63889 hasResults: False